The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Hypotension, Consciousness, Level Altered, Airway Disease, Respiratory Failure, Tachypnea, Bradypnea, Tachycardia, Bradycardia, Cardiac Failure, Cardiac Arrest

In brief

Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.

Key facts

Study ID
NCT06503016
Run by
Università Vita-Salute San Raffaele
People needed
400
Starts
2024-10-08
Expected to finish
2026-07-01
Last updated by the study team
2025-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.